Table 1

Flowchart of patient follow-up

	Screening	Inclusion D0	Study period	Death/30 days	Follow-up 6 months
Baseline information
Demographic data and history	√	√
Inclusion and exclusion criteria	√
Written informed consent	√
Diagnosis and focus of infection	√	√	√
Vital signs		√
APACHEII/SOFA		√	√D1, 3, 7
Efficacy observation
Cardiac function assessment (CI, LVEF)	√	√	√D1, 3, 5, 7, 10, 14	√	√
ECMO intervention			√
Treatment with vesopressor	√	√	√
Mechanical ventilation		√	√
CRRT implication		√	√
Laboratory tests	√	√	√D1, 3, 5, 7
Safety observation
Complications of ECMO			√
Adverse event			√
Additional observation
ICU and hospital LOS				√
Alive or dead status				√	√
Life quality (EQ-5D score)					√

APACHEII, Acute Physiology and Chronic Health Evaluation II; CI, cardiac index; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; LOS, length of stay; SOFA, Sequential Organ Failure Assessment.